Shares of Amedisys (NASDAQ: AMED) fell by 4% as concerns grow regarding the potential acquisition by UnitedHealth Group (NYSE: UNH). The decline in Amedisys’s stock comes amid reports suggesting that the U.S. Department of Justice (DOJ) may be leaning toward filing a lawsuit to block the deal due to potential antitrust issues.
This news has raised uncertainty about the future of the acquisition, as a lawsuit from the DOJ could delay or derail the merger. The deal, which aims to expand UnitedHealth’s footprint in the home healthcare market, has sparked concerns about market competition.
Investors are now wary, as a regulatory challenge could prevent the deal from going through or lead to unfavorable terms. As the situation develops, Amedisys’s stock will likely continue to experience volatility tied to the outcome of the DOJ’s review.
